RIGL Rigel Pharmaceuticals Inc.

2.35
-0.01  -0%
Previous Close 2.36
Open 2.37
Price To Book 3.79
Market Cap 391605109
Shares 166,640,472
Volume 1,101,058
Short Ratio
Av. Daily Volume 2,367,914

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released April 3, 2018. Primary endpoint not met.
Fostamatinib
IgA nephropathy
Phase 2 trial did not meet endpoints
R348
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Approved April 17, 2018.
Tavalissetm (Fostamatinib)
Immune Thrombocytopenic Purpura (ITP)
Phase 3 trial to commence 1H 2019.
Fostamatinib
Autoimmune hemolytic anemia (AIHA)
Phase 1 trial initiation announced June 26, 2018.
R835
Autoimmune and inflammatory diseases

Latest News

  1. Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results
  2. Is Rigel Pharmaceuticals a Buy?
  3. Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings
  4. Rigel Rises On European Marketing Agreement For Autoimmune Drug
  5. 4 Healthcare Stocks Making Moves On Wednesday (1/23/19)
  6. Rigel Pharmaceuticals stock up 9% after announcing licensing agreement with Grifols
  7. Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
  8. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): When Will It Breakeven?
  9. Rigel Pharmaceuticals Provides Business Update
  10. Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference
  11. Rigel Pharmaceuticals, Inc. (RIGL): Hedge Fund Sentiment Unchanged
  12. Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved
  13. Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City
  14. New Research Coverage Highlights Weight Watchers International, Rudolph Technologies, Lowe's Companies, Net 1 UEPS Technologies, Viasat, and Rigel Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
  15. What does Rigel Pharmaceuticals Inc’s (NASDAQ:RIGL) Balance Sheet Tell Us About Its Future?
  16. Implied Volatility Surging for Rigel Pharmaceuticals (RIGL) Stock Options
  17. Edited Transcript of RIGL earnings conference call or presentation 6-Nov-18 10:00pm GMT
  18. Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates
  19. Rigel: 3Q Earnings Snapshot
  20. Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update